The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InTonix Pharmaceuticals announced the peer-reviewed publication of steady-state pharmacokinetic data for its drug, TONMYA, in the journal Clinical Pharmacology in Drug Development. The published data confirms the drug's clinical profile following 20 days of daily dosing, providing essential scientific validation for the treatment. TONMYA stands as the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years, marking a significant breakthrough in the field. By providing clinical transparency, the company aims to strengthen the market position of its lead product. This scientific milestone is expected to bolster investor confidence in the company's biotech valuation and clinical pipeline. The publication underscores Tonix's commitment to rigorous scientific standards for its newly approved therapies.